Hologic, Inc. (NASDAQ:HOLX) – Stock analysts at William Blair issued their Q4 2017 earnings per share (EPS) estimates for Hologic in a research report issued on Tuesday. William Blair analyst B. Weinstein anticipates that the medical equipment provider will post earnings per share of $0.49 for the quarter. William Blair also issued estimates for Hologic’s Q1 2018 earnings at $0.52 EPS, Q2 2018 earnings at $0.52 EPS, Q3 2018 earnings at $0.54 EPS and Q4 2018 earnings at $0.53 EPS.

Several other brokerages have also recently issued reports on HOLX. Zacks Investment Research cut shares of Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. Royal Bank Of Canada reduced their price target on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research report on Thursday, August 3rd. Deutsche Bank AG reduced their price target on shares of Hologic from $51.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. Barclays PLC reduced their price target on shares of Hologic from $53.00 to $51.00 and set an “overweight” rating on the stock in a research report on Thursday, August 3rd. Finally, Piper Jaffray Companies restated a “buy” rating and set a $51.00 target price on shares of Hologic in a research note on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $48.64.

WARNING: This report was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/14/william-blair-comments-on-hologic-inc-s-q4-2017-earnings-holx.html.

Hologic (NASDAQ HOLX) opened at 37.56 on Wednesday. Hologic has a 52-week low of $35.15 and a 52-week high of $46.80. The stock has a market cap of $10.53 billion, a P/E ratio of 13.99 and a beta of 0.92. The firm’s 50-day moving average is $39.52 and its 200-day moving average is $42.67.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. The business had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.51 EPS.

A number of institutional investors have recently bought and sold shares of the stock. Strs Ohio grew its holdings in Hologic by 11.0% in the 1st quarter. Strs Ohio now owns 28,657 shares of the medical equipment provider’s stock valued at $1,219,000 after buying an additional 2,837 shares during the period. Russell Investments Group Ltd. grew its holdings in Hologic by 10.4% in the 1st quarter. Russell Investments Group Ltd. now owns 321,371 shares of the medical equipment provider’s stock valued at $13,678,000 after buying an additional 30,190 shares during the period. Oregon Public Employees Retirement Fund grew its holdings in Hologic by 15.2% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 29,166 shares of the medical equipment provider’s stock valued at $1,241,000 after buying an additional 3,843 shares during the period. Advisors Asset Management Inc. grew its holdings in Hologic by 40.4% in the 1st quarter. Advisors Asset Management Inc. now owns 15,462 shares of the medical equipment provider’s stock valued at $658,000 after buying an additional 4,453 shares during the period. Finally, Meadow Creek Investment Management LLC grew its holdings in Hologic by 9.9% in the 1st quarter. Meadow Creek Investment Management LLC now owns 7,104 shares of the medical equipment provider’s stock valued at $302,000 after buying an additional 640 shares during the period. Hedge funds and other institutional investors own 96.39% of the company’s stock.

In related news, Director Elaine Ullian sold 8,849 shares of Hologic stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $45.28, for a total transaction of $400,682.72. Following the completion of the sale, the director now owns 23,810 shares in the company, valued at approximately $1,078,116.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Karleen Marie Oberton sold 4,704 shares of Hologic stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $45.19, for a total value of $212,573.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 27,594 shares of company stock valued at $1,168,871. 0.79% of the stock is currently owned by company insiders.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.